Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn’t sitting well with shareholders, primarily because CRMD’s topline was roughly $400 million in the prior year, according to the preliminary full-year financials it posted on Thursday. Simply put, […]